Establishment Labs (NASDAQ:ESTA) Reaches New 52-Week High on Strong Earnings

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $55.00 and last traded at $53.6280, with a volume of 6273 shares trading hands. The stock had previously closed at $49.40.

The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same period last year, the business earned ($0.59) EPS. Establishment Labs has set its FY 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ESTA. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a research report on Sunday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Establishment Labs in a report on Wednesday, October 8th. Canaccord Genuity Group began coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective for the company. Finally, Mizuho boosted their target price on Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.50.

Institutional Investors Weigh In On Establishment Labs

Large investors have recently bought and sold shares of the stock. CenterBook Partners LP acquired a new stake in Establishment Labs in the second quarter valued at approximately $16,204,000. Viking Global Investors LP purchased a new stake in shares of Establishment Labs during the second quarter valued at approximately $14,669,000. First Light Asset Management LLC bought a new position in Establishment Labs in the 1st quarter valued at $13,746,000. Nuveen LLC bought a new position in Establishment Labs during the first quarter valued at about $13,054,000. Finally, Woodson Capital Management LP lifted its stake in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after purchasing an additional 255,000 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Stock Performance

The company has a 50 day simple moving average of $42.82 and a 200-day simple moving average of $39.84. The stock has a market capitalization of $1.57 billion, a P/E ratio of -17.67 and a beta of 0.98. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.